BTIG has maintained its Neutral rating on Insight Molecular's stock in light of the ongoing review by the U.S. Food and Drug Administration (FDA). The firm continues to monitor the situation closely as the FDA evaluates the company's submissions. This decision reflects BTIG's cautious stance regarding the potential impact of the regulatory process on Insight Molecular's market performance.
Related Articles
Don't miss out on breaking stories and in-depth articles.